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Abstract
Background: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information.
Objective: The objective of this study was to assess the usability and acceptability of the iPrevent prototype.
Methods: Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics
clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with
iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients.
Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using
iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent.
Data were summarized using descriptive statistics.
Results: The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was
above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by
iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37),
respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long.
Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC
prevention knowledge without changing state anxiety.
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Conclusions: The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be
an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent.
(JMIR Formativ Res 2018;2(2):e24)   doi:10.2196/formative.9935
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Introduction
Breast cancer (BC) is a major public health problem, accounting
for over 2 million cases worldwide each year [1]. In addition
to population-based educational and public health policy
interventions to minimize exposure to modifiable BC risk factors
and optimize cancer screening, identifying women at increased
risk and implementing risk-stratified, evidence-based prevention
and intensified screening strategies for them is a priority [2].
Health care providers often have difficulty assessing and
communicating BC risk as well as the absolute benefits and
disadvantages of risk management interventions such as
risk-reducing medication, surgery, and cancer screening [3,4].
Several tools exist to estimate BC risk based on personal risk
factors, but none provides risk-adapted, individually-tailored,
risk management information [5,6]. iPrevent was designed to
help women and their health care providers, including primary
care physicians (PCP), breast surgeons (BS), and genetics
clinicians (GC), to assess and manage BC risk collaboratively
[7]. It integrates BC risk estimation, using either the
International Breast Cancer Intervention Study model or the
Breast and Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm model (as appropriate for the woman’s
risk factors), with tailored risk management information [8-10].
iPrevent users are first given a qualitative risk estimate according
to Cancer Australia definitions: average or slightly above
average risk (<1.5 times population risk at that age), moderately
increased risk (1.5-3 times population risk), or high risk (>3
times population risk) [11]. Women can then choose to see their
risk information displayed as a percentage, a pictogram, and a
graph. Women are also provided with a menu of risk
management strategies appropriate to their risk category, based
on Australian National Guidelines [11], with more detailed
optional information about each strategy, including estimates
of the absolute (rather than relative) risk reductions for each
medical and surgical intervention and tailored lifestyle advice.
The aims of this pilot study of patients and their clinicians were
to assess the iPrevent prototype with regard to its clinical
usability and the acceptability of its content and layout and to
identify potential barriers to its implementation. Exploratory
aims included assessing its potential impact on patient risk
perception, anxiety, BC worry, and BC prevention knowledge.
Methods
Study Setting
Stage 1 piloting was undertaken by the researchers with women
who had previously received risk assessment and risk
management advice at the Peter MacCallum Cancer Centre
(PMCC) Breast and Ovarian Cancer Risk Management Clinic
[12]. Stage 2 piloting involved PCP, BS, and GC in public
hospitals and private primary care and breast and genetics clinics
as well as their patients. Patients and clinicians were not selected
according to their level of BC risk or prior experience with BC
risk assessment.
Eligibility Criteria
Eligible patients were women aged 18-70 years with no personal
history of cancer who provided written informed consent.
Patients with previous risk-reducing bilateral mastectomy or
major medical comorbidities were excluded. Eligible clinicians
were PCP, BS, or GC with a workplace computer with Web
access. English proficiency was required for all participants.
This study was approved by the Human Research and Ethics
Committees of the University of Melbourne and the PMCC. All
procedures performed in studies involving human participants
were in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical
standards.
Stage 1: Piloting on Patients With Prior Risk
Assessment
We enrolled 10 patients from the PMCC Breast and Ovarian
Cancer Risk Management Clinic. Baseline information on age,
education, computer literacy [13], and both the perceived BC
risk category (average, somewhat increased, or substantially
increased) [11] and perceived percentage lifetime BC risk were
collected. Patients then used iPrevent under the supervision of
a research assistant (PW or ES). The time for data input was
recorded. Patients were emailed the report in a PDF format.
Two weeks after using iPrevent, they completed a questionnaire
assessing usability and acceptability of iPrevent, knowledge,
and psychosocial outcomes. They could review the emailed
iPrevent output while answering these questions.
System Usability Scale
This 10-item instrument [14] uses a 5-point Likert rating scale
from “strongly agree” to “strongly disagree” to measure product
usability. It is applicable to small samples [15] and correlates
well with other subjective measures of usability [16,17]. Final
scores range from 0-100, and a System Usability Scale (SUS)
score >68 is considered above average.
iPrevent Acceptability Questionnaire
This 9-item measure, adapted from a previous evaluation of a
decision aid [18], uses Likert scales to elicit perceptions of the
length, clarity, balance, and usefulness of iPrevent.
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Breast Cancer Risk Perception
This single item, adapted from a study measuring the impact of
genetic counseling, asks patients about their BC risk category:
“average,” “somewhat increased,” or “substantially increased”
[19]. Women were classified as underestimators, accurate
estimators, or overestimators based on comparison with the risk
estimated by iPrevent.
Breast Cancer Worry Scale
The Lerman BC worry scale is a 3-item scale. Higher scores
indicate increased frequency and impact of worry [20].
Spielberger State-Trait Anxiety Inventory
The short form State-Trait Anxiety Inventory (STAI; 6 items)
measures state anxiety; higher scores indicate higher anxiety
[21].
Breast Cancer Prevention Knowledge
We used 16 items assessing knowledge regarding BC (11 items),
risk-reducing medication (3 items), and risk-reducing
mastectomy (2 items), which were adapted from published
knowledge measures (see Multimedia Appendix 1) [22,23].
Although every woman was asked to answer all questions, the
number of responses scored for each participant was dependent
on the iPrevent-determined risk category. All average-risk
women and moderate-risk women who were aged <35 years
were assessed only on BC knowledge questions. Older,
moderate-risk women were also assessed on risk-reducing
medication questions. High-risk women were assessed on all
16 questions. The proportion of correct responses was calculated.
Stage 2: Piloting With Clinicians and Their Patients
We recruited 20 clinicians from previous focus groups [3-4] (5
BS and 3 PCP), via email invitation from KAP (1 BS and 6
GC), and through the PMCC PCP liaison officer (5 PCP).
Clinicians first underwent an iPrevent “familiarization” session.
Supervised by a research assistant (PW or ES), clinicians first
entered data into iPrevent on 3 hypothetical patients (high,
moderate, and average risk) and reviewed the iPrevent output
information. On the same day, clinicians then conducted 2 mock
consultations with female actors: one at high risk and the other
moderate risk. Patient (actor) information was pre-entered into
iPrevent, and clinicians were asked to use the iPrevent output
with the actors as they might in a clinical consultation.
Clinicians were then asked to invite 3 eligible patients from
their practice (either during patient appointments or via
telephone prior) during the following 3 months to participate
by entering their information into iPrevent prior to a consultation
and attending an appointment with the clinician to receive the
“output.” Patients were provided a printout of their iPrevent
output via email. Clinicians recorded the amount of time spent
using iPrevent.
All patients were asked to complete the same pre- and
post-iPrevent assessments as in Stage 1. Clinicians completed
the SUS and Acceptability questionnaires 2 weeks after
recruitment of 3 patients (or 3 months after familiarization, if
full patient recruitment did not occur).
Statistical Analyses
All statistical analyses were performed in R 3.2.3 (R Core Team,
2015). The planned sample size of 20 clinicians and 60 patients
was based on pragmatic estimates of the numbers it was
considered possible to recruit over the available time period.
The purpose of the study was to assess the acceptability and
usability of iPrevent for clinicians and patients and not to test
hypotheses. Therefore, descriptive statistics were used to
summarize the data (mean, median, and range for continuous
variables and counts and percentages for categorical variables).
Patient and clinician data were analyzed separately. A pairwise
t test was used to assess whether the STAI score changed from
pre- to post-iPrevent assessment.
Results
Participants
We recruited 20 clinicians and 43 patients (10 for Stage 1 and
33 for Stage 2). Clinicians only recruited 33 of the planned 60
patients (planned 3 per clinician). BS (n=6) recruited 16 of a
planned 18 patients, GC (n=6) recruited 14 of a planned 18
patients (1 GC moved overseas during the study and was, thus,
unable to recruit her 3 planned patients), and PCP (n=8)
recruited only 3 of a planned 28 patients.
Participant Characteristics
Patient characteristics are shown in Table 1. Median age was
38 years (range 21-56 years), 74% (31/42) had a university
education, and 51% (22/43 were at moderate risk for BC.
Clinician characteristics are shown in Table 2. Their median
age was 47 years (range 28-66 years); of all clinicians, 40%
(8/20) were PCP, 30% (6/20) were BS, and all but 15% (3/20)
were females. The majority used computers often and rated
themselves as having good computer skills.
iPrevent Data Entry and Consultation Times
Patients took a median of 15 (range 5-60) minutes to enter their
risk factor data. The median time taken for clinician
consultations in which iPrevent data were discussed was 20
(range 5-45) minutes.
System Usability Scale
SUS responses are summarized in Figure 1. Data were missing
for 6 patients and 1 clinician who did not return the
questionnaire. Overall, 76% (28/37) patients and 68% (13/19)
clinicians rated iPrevent usability as above average (SUS score
>68).
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Table 1. Patient characteristics (N=43).
ValueCharacteristic
38 (21-56)Age in yearsa, median (range)












Sources of information on breast cancer (BC) risk in the past, n (%)a
30 (71)Health professional
19 (45)Family and friends
10 (24)Internet
6 (14)Health information booklets
4 (10)Support organizations




“Do you feel like you know what your own risk of breast cancer is?” n (%)b
12 (29)Don’t know my risk
25 (61)I think I know my risk
4 (10)Confident I know my risk
aData missing for1 patient.
bData missing for 2 patients.
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Table 2. Clinician characteristics (N=20).
ValueCharacteristic














8 (40)Primary care physician
1 (5)Medical oncologist
16 (1–34)Number of years working in specialty, median (range)
138 (4–960)How many patients per year would you discuss breast cancer risk with? Median (range)
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Figure 1. iPrevent System Usability Scale scores for clinicians and patients.
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Table 3. iPrevent acceptability among clinicians and patients.
Patient, n (%)Clinician, n (%)Acceptability assessment
The amount of information provided isa,b
1 (3)0 (0)Too much
3 (8)2 (11)A little too much
33 (89)17 (89)About right
The length of the tool isa,b
0 (0)4 (21)Much too long
10 (27)6 (32)A little too long
27 (73)9 (47)About right
Clarity of informationa,b
7 (19)8 (42)Very clear
16 (43)5 (26)Mostly clear
13 (35)5 (26)About right
1 (3)1 (5)Not clear
Regarding cancer prevention, how balanced did the information seemb,c
9 (24)3 (17)Biased toward prevention
26 (70)14 (78)Completely balanced
2 (5)1 (6)Biased against prevention





How helpful with regard to making a decision about BC risk managementa,b
19 (51)9 (47)Very helpful
13 (35)7 (37)Somewhat helpful
5 (14)3 (16)A little helpful
Recommend this tool to othersa,b
18 (49)12 (63)Definitely
18 (49)6 (32)Probably
1 (3)1 (5)Probably not
How simple to navigate through the toola,b
21 (57)7 (37)Very easy
15 (41)11 (58)Somewhat easy
1 (3)1 (5)Not easy
Easy to reada,b
22 (59)8 (42)Very easy
15 (41)11 (58)Somewhat easy
an=19 clinicians because of missing data for 1 clinician.
bn=37 patients because of missing data for 6 patients.
cn=18 clinicians because of missing data for 2 clinicians.
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Table 3 shows that iPrevent was generally acceptable to study
participants. Of all, 89% (17/19) clinicians and 89% (33/37)
patients reported that the amount of information provided by
iPrevent was “about right.” Furthermore, 53% (10/19) clinicians
and 27% (10/37) patients reported that iPrevent was too long.
Only 1 patient and 1 clinician reported that the information was
not clear and that they would “probably not” recommend
iPrevent to others.
Exploratory Endpoints
Breast Cancer Risk Perception
Of patients who completed the relevant questions before
iPrevent, 40% (14/35) correctly indicated their BC risk category,
but 51% (18/35) overestimated and 9% (3/35) underestimated
their BC risk category. Post-iPrevent, 86% (30/35) accurately
estimated their risk category, although 11% (4/35) and 3% (1/35)
continued to overestimate and underestimate their risk,
respectively.
Breast Cancer Worry Scale
Pre-iPrevent, 26% (11/42) women reported worrying about BC
“often” or “all the time,” while 19% (7/37) women reported this
after iPrevent. Regarding the impact of BC worry on mood and
daily activities, 69% (29/42) patients reported a low score (1-1.5
out of 4) pre-iPrevent. When this was compared before and after
iPrevent, 25% (9/36) patients reported less impact, 47% (17/36)
reported no change, and 28% (10/36) reported more impact.
Spielberger State-Trait Anxiety Inventory
The mean short form STAI score (maximum 24) pre-iPrevent
was 11.3 (SD 3.8) with no significant change post-iPrevent
(median increase of 1, 95% CI: 0.5-2; P=.14).
Breast Cancer Prevention Knowledge
Overall BC prevention knowledge improved for all risk groups.
(Multimedia Appendices 1 and 2).
Discussion
This pilot study of the iPrevent prototype has found good
usability and acceptability without evidence of an adverse impact
on anxiety or BC worry. The observation that the 8 PCP
recruited only 3 patients between them in the required 3-month
period suggests that implementation of iPrevent into primary
care might be substantially more challenging than
implementation into the specialist setting, where recruitment of
patients was much higher. Another interpretation is that the
study requirements (eg, obtaining written informed consent)
were onerous, especially for PCP in busy practices, and thus,
the low recruitment by PCP in this study might not reflect the
uptake of iPrevent in routine practice. However, as earlier focus
groups had highlighted that PCP generally do not see BC risk
assessment and management as being in their domain, iPrevent
might be able to contribute to overcoming provider unfamiliarity
and lack of confidence for this group of clinicians [3].
The prototype was considered too long by a majority of
clinicians and some patients, indicating another potential barrier
to implementation. Patients took a median of 15 minutes and
up to 60 minutes to enter their risk factor data, and the
subsequent median time taken for the clinician consultation
using the iPrevent output was 20 minutes. To address this issue,
we have now incorporated changes to streamline the data entry
for family history. This study also highlighted the need for
patients to be able to enter their data into iPrevent at home prior
to a consultation.
iPrevent may improve BC risk perception given an additional
46% (16/35) patients accurately estimated their BC risk category
after using iPrevent. As a higher perceived risk of BC is
associated with considering medical prevention and
risk-reducing surgery among high-risk women [24-26], iPrevent
could become a potential behavior-modifying tool. While this
pilot study provides no information about the uptake of risk
management strategies after using iPrevent, this issue will be
an important endpoint for future larger studies. Other studies
have found that women who have access to more thorough
information from genetic counselors, combined with support
to make decisions, have a higher uptake of risk reduction
methods [27-29]; thus, we hypothesize that iPrevent might have
a similar impact.
Use of iPrevent did not appear to increase patient worry or
anxiety, consistent with the literature that has found that
decreased anxiety and better psychological outcomes are
associated with improved accuracy of perceived risk [24,30,31].
Use of iPrevent seemed to improve BC knowledge, a recognized
critical first step in helping individuals understand screening
options, weigh potential benefits and risks for risk-reducing
measures, and make informed decisions [32-34]. In addition,
89% (33/37) patients indicated that some or most of the
information contained in iPrevent was new to them (Table 3).
This pilot had several limitations. First, the sample was small
and the study did not achieve its target patient recruitment. The
majority of patients were young and highly educated, so the
acceptability and usability of iPrevent might differ in the general
community where computer literacy might be lower. Similarly,
clinicians who chose to participate could have been more highly
engaged with BC risk assessment and risk management than
nonparticipant clinicians. Finally, only short-term outcomes
were measured, and the impact on long-term satisfaction and
uptake of BC risk-reducing measures could not be determined.
As a result of this study, enhancements have been made to
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